ArticleFrontiers in pharmacology2021
An Open Access Database of Licensed Cancer Drugs.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Pasta, a Versatile Transcriptomic Clock, Maps the Chemical and Genetic Determinants of Aging and Rejuvenation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Systemic anti-cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy.International journal of cancer · 2026Article
- ProteinNetworkSight: a user-friendly platform for transforming co-expression patterns into actionable therapeutic insights through interactive network visualization.Nucleic acids research · 2026Article
- Discovery and development of steroidal enzyme inhibitors as anti-cancer drugs: state-of-the-art and future perspectives.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Cell-cell interactions as predictive and prognostic markers for drug responses in cancer.Genome medicine · 2025Review
- Geographic Variation in the Utilization of Cancer Care From Subspecialized Medical Oncologists in the United States, 2008 to 2020.Annals of internal medicine · 2025Article
- ACLPred: an explainable machine learning and tree-based ensemble model for anticancer ligand prediction.Scientific reports · 2025Article
- Network-based approach identifies key genes associated with tumor heterogeneity in HPV positive and negative head and neck cancer patients.Scientific reports · 2025Article
- CLCluster: A redundancy-reduction contrastive learning-based clustering method of cancer subtype based on multi-omics data.Molecular therapy. Nucleic acids · 2025Article
- An analysis of compassionate access programmes for novel oncology drugs.Irish journal of medical science · 2025Article
- Inferring Drug-Gene Relationships in Cancer Using Literature-Augmented Large Language Models.Cancer research communications · 2025Article
- Drug Repurposing: A Conduit to Unravelling Metabolic Reprogramming for Cancer Treatment.Mini reviews in medicinal chemistry · 2025Review
- OncoAID: an open access targeted anti-cancer drugs database.Frontiers in pharmacology · 2025Article
- OncoProExp: An interactive shiny web application for comprehensive cancer proteomics and phosphoproteomics analysis.Computational and structural biotechnology journal · 2025Article
- Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations.Computational and structural biotechnology journal · 2025Article
- Cancer pharmacoinformatics: Databases and analytical tools.Functional & integrative genomics · 2024Review
- Advanced therapies in orthopaedics.EFORT open reviews · 2024Review
- In vitro results with minimal blood toxicity of a combretastatin A4 analogue.Investigational new drugs · 2024Article
- DrugMetric: quantitative drug-likeness scoring based on chemical space distance.Briefings in bioinformatics · 2024Article
- Network-based approach elucidates critical genes in BRCA subtypes and chemotherapy response in triple negative breast cancer.iScience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A global, comprehensive and open access listing of approved anticancer drugs does not currently exist. Partial information is available from multiple sources, including regulatory authorities, national formularies and scientific agencies. Many such data sources include drugs used in oncology for supportive care, diagnostic or other non-antineoplastic uses. We describe a methodology to combine and cleanse relevant data from multiple sources to produce an open access database of drugs licensed specifically for therapeutic antineoplastic purposes. The resulting list is provided as an open access database, (http://www.redo-project.org/cancer-drugs-db/), so that it may be used by researchers as input for further research projects, for example literature-based text mining for drug repurposing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.